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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a
significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in
the lungs, of GSK3008348, a novel inhaled alpha-v beta-6 (αvβ6) integrin inhibitor, in participants with IPF.
Methods: This was a phase 1b, randomised, double-blind (sponsor unblind) study, conducted in the UK (two
clinical sites, one imaging unit) between June 2017 and July 2018 (NCT03069989). Participants with a definite or
probable diagnosis of IPF received a single nebulised dose of 1000 mcg GSK3008348 or placebo (ratio 5:2) in two
dosing periods. In period 1, safety and PK assessments were performed up to 24 h post-dose; in period 2, after a 7-
day to 28-day washout, participants underwent a total of three positron emission tomography (PET) scans: baseline,
Day 1 (~ 30 min post-dosing) and Day 2 (~ 24 h post-dosing), using a radiolabelled αvβ6-specific ligand, [18F]FB-
A20FMDV2. The primary endpoint was whole lung volume of distribution (VT), not corrected for air volume, at ~ 30
min post-dose compared with pre-dose. The study success criterion, determined using Bayesian analysis, was a
posterior probability (true % reduction in VT > 0%) of ≥80%.
Results: Eight participants with IPF were enrolled and seven completed the study. Adjusted posterior median
reduction in uncorrected VT at ~ 30 min after GSK3008348 inhalation was 20% (95% CrI: − 9 to 42%). The posterior
probability that the true % reduction in VT > 0% was 93%. GSK3008348 was well tolerated with no reports of serious
adverse events or clinically significant abnormalities that were attributable to study treatment. PK was successfully
characterised showing rapid absorption followed by a multiphasic elimination.
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Conclusions: This study demonstrated engagement of the αvβ6 integrin target in the lung following nebulised
dosing with GSK3008348 to participants with IPF. To the best of our knowledge this is the first time a target-specific
PET radioligand has been used to assess target engagement in the lung, not least for an inhaled drug.
Trial registration: clinicaltrials.gov: NCT03069989; date of registration: 3 March 2017.
Keywords: Alpha-v beta-6, αvβ6, Integrin, Idiopathic pulmonary fibrosis, IPF, positron emission tomography, PET,
[18F]FB-A20FMDV2, target engagement
Background
Idiopathic pulmonary fibrosis (IPF) is a specific form of
chronic, progressive interstitial pneumonia of unknown
cause [1, 2]. It occurs primarily in adults and the clinical
course varies amongst diagnosed individuals from slow
progression to acute decompensation and death, with a
median survival time in untreated patients of just 2 to 4
years [1, 2]. Pharmacological treatment is currently lim-
ited to two oral anti-fibrotics, pirfenidone and ninteda-
nib, both of which have been shown to reduce the rate
of decline in lung function but are associated with sig-
nificant side effects [2]. There remains a considerable
unmet need for new therapies to treat this disease.
The alpha-v beta-6 (αvβ6) integrin has a major role in
the activation of transforming growth factor-β (TGFβ), a
cytokine that is central to the development of IPF [3].
The expression of αvβ6 is upregulated in IPF lung tissue
[4], and increased levels of αvβ6 are associated with dis-
ease progression and poor prognosis [5], suggesting that
an inhibitor of αvβ6 may provide therapeutic benefits to
patients with IPF. GSK3008348 is a novel, small mol-
ecule αvβ6 integrin inhibitor that has been developed for
inhaled delivery via nebulisation and is the first inhaled
compound in this class [6]. In vitro, GSK3008348 dem-
onstrates selective and high affinity binding to the αvβ6
integrin, inducing fast internalisation and degradation of
the integrin. In an in vivo mouse model of lung fibrosis,
inhaled GSK3008348 inhibited the activation of TGFβ
[7]. GSK3008348 has previously been demonstrated to
be well tolerated at single doses up to 3000 mcg in
healthy human participants, with a pharmacokinetic
(PK) profile that was dose proportional at potentially
clinically relevant doses [8].
Positron emission tomography (PET) imaging using the
αvβ6-selective [18F]FB-A20FMDV2 PET ligand provides a
non-invasive method for measuring αvβ6 expression and a
potential model for assessing target engagement of inhaled
therapies in the lung [9, 10]. In a study of 15 participants (6
healthy, 9 with pulmonary fibrosis), lung uptake of [18F]FB-
A20FMDV2 measured by lung volume of distribution (VT),
a partition co-efficient that acts as a marker of expression
of the integrin αvβ6, was successfully quantified. This dem-
onstrated increased expression in IPF compared with
healthy participants [10]. Additionally, [18F]FB-A20FMDV2
was well-tolerated and the PET measures were reproducible
over a two-week period. An independent study has recently
reported similar results with an alternative αvβ6-specific
PET ligand ([18F]FP-R01-MG-F2) [11].
The aim of this study was to evaluate the safety, toler-
ability and PK of GSK3008348 in participants with IPF
and to obtain preliminary information on target engage-
ment using the [18F]FB-A20FMDV2 PET ligand.
Methods
Study design
This phase 1b study was conducted at three centres in the
UK (two clinical sites [Royal Brompton Hospital and Uni-
versity College London Hospital, London, UK] and one
imaging unit [Invicro, London, UK]) between June 2017
and July 2018. The study was designed to comprise up to
two cohorts (cohort 2 was optional) (Study 204,715,
NCT03069989). In cohort 1, under double-blind (sponsor
unblind) conditions, participants were randomised 5:2 to
receive a single nebulised dose of either 1000 mcg
GSK3008348 or placebo in two dosing periods (Fig. 1).
Dosing period 1 was to assess safety and PK; partici-
pants remained in the clinical unit overnight to enable
regular safety and PK assessments up to 24 h post-dose.
Dosing period 2 was to enable assessment of target en-
gagement. After a wash out period of 7 to 28 days fol-
lowing the first dose, participants attended the imaging
unit on an outpatient basis for a pre-dose PET scan
(pre-dose PET), to determine baseline levels of pulmon-
ary uptake of the αvβ6-specific tracer, as well as a high-
resolution computed tomography (HRCT) scan. Follow-
ing the baseline scan, participants attended the clinical
unit for safety assessments and once deemed fit to con-
tinue, attended the imaging unit for their second dose of
study medication and post-dose PET scans: Day 1 [~ 30
min post-dosing (PET 1)] and Day 2 [~ 24 h post-dosing
(PET 2)]. There was a maximum of 14 days between the
baseline PET scan and the PET scan on Day 1.
Optional cohort 2 was to enable further exploration of
the safety of GSK3008348 and/or target engagement if
required. Following completion of cohort 1, no safety
signals emerged that warranted further investigation and
the pre-defined study success criterion for GSK3008348
target engagement was met. This, together with the
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operational complexities of the study, led to the decision
to stop the study prior to progression to cohort 2.
To ensure consistency of nebulised dosing the same
model of Philips Sidestream Plus nebuliser (Philips,
Guildford, United Kingdom) was used at each site. The
1000 mcg dose was selected for two reasons;
1) It was lower than the maximum 3000 mcg dose
used in healthy volunteers, which would enable
significant safety margins in the event that systemic
exposure was higher in IPF patients than healthy
volunteers.
2) PK from the study in healthy participants [10],
demonstrated peak systemic unbound
concentrations at 1000 mcg that were significantly
in excess of the in vitro dissociation constant (Kd).
As lung tissue exposures are likely to be at least as
high as the systemic exposure, it was expected that
αvβ6 would demonstrate significant engagement at
this dose.
The study was approved by the National Research Eth-
ics Service Committee London and the Administration
of Radioactive Substances Advisory Committee of the
UK. Written informed consent was obtained from all
participants.
Participants
Eligible participants were male (aged ≥50 years) or
female (aged ≥55 years) with a definite or probable diag-
nosis of IPF [12], forced vital capacity (FVC) > 50% pre-
dicted and diffusing capacity of the lungs for carbon
monoxide (DLCO) > 40% predicted. Body weight was
required to be ≥45 kg and body mass index within the
range of 18.5 to 35.0 kg/m2. Participants who were
currently taking pirfenidone or nintedanib (or who had
received either within 30 days of the first dose of study
treatment), had a current IPF exacerbation or respiratory
tract infection, a post-bronchodilator forced expiratory
volume in 1 s (FEV1)/ FVC ratio < 0.70, or known
hepatic or biliary abnormalities were excluded. Full de-




Dynamic [18F]FB-A20FMDV2PET scans were acquired
using a Siemens PET/CT system Biograph 6 TruePoint
with TrueV or a Hi-Rez Biograph 6 (Siemens Health-
care, Erlangen, Germany). Full details of the method-
ology for image acquisition and analysis have been
detailed elsewhere [10]. In brief, for each PET scan,
[18F]FB-A20FMDV2 was injected into a cubital or fore-
arm vein through an intravenous cannula and emission
data were acquired for up to 90min. An additional ven-
ous cannula was used to collect blood samples through-
out the PET scan for quantification of the total and
unmetabolized [18F]FB-A20FMDV2-related radioactivity
in whole blood and plasma. These data were used along-
side the images to derive an input function for the ana-
lysis of emission PET data based on a volume of interest
(VOI) in the descending aorta. Using time activity curves
from the whole lung VOI, PET outcome parameters of
dynamic VT, a partition coefficient derived using a kin-
etic model, and static standardised uptake value (SUV),
integrated from 10 to 30 mins post tracer administra-
tion, were obtained. Both VT and SUV measures were
expressed with and without correction for air volume –
referred to as air-corrected VT and SUV and uncor-
rected VT and SUV from here on.
The primary pharmacodynamic endpoint was the
change in the uptake of [18F]FB-A20FMDV2 in the
whole lung, assessed as uncorrected VT at ~ 30 min
post-dose compared with pre-dose. VT was chosen a
priori as the appropriate measure to assess uptake of the
αvβ6 PET ligand as it intrinsically accounts within the
kinetic model for any distributional changes in the lig-
and, for example altered blood kinetics, that may be
caused by the effects of a therapeutic αvβ6 inhibitor.
Fig. 1 Study schematic for cohort 1. HRCT: high-resolution computed tomography; PET: positron emission tomography; PK: pharmacokinetics;
PET1: PET scan on day 1 at ~30 min post-dose; PET2: PET scan on day 2 at ~24 h post-dose
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The total maximum effective radiation dose received
per participant was estimated to be 20.9 mSv [13], com-
prised of three PET scans each with up to two low-dose
computed tomography scans for attenuation correction,
and a HRCT scan which was performed once only at
baseline in dosing period 2 for anatomical localisation.
Safety assessments
Full safety assessments were conducted at screening,
pre-dose baseline and at regular intervals during each
dosing period, including vital signs (blood pressure,
heart rate, respiratory rate and temperature), 12-lead
electrocardiograms (ECGs), routine safety laboratory
tests and lung function. Oxygen saturation was mea-
sured continuously from pre-dose to 4 h post-dose in
dosing period 1. Adverse events (AEs) were monitored
throughout the study.
Pharmacokinetic assessments
PK blood samples (2 mL) were collected at pre-dose, and
at 15 and 30 min, 1, 2, 4, 8, 12, 18 and 24 h post-dose in
dosing period 1, and on Day 1 (pre-dose, 15 and 30min,
2 and 4 h post-dose) and Day 2 (on arrival and discharge
at the imaging unit) in dosing period 2. Plasma samples
were analysed for GSK3008348 using a validated analyt-
ical method based on protein precipitation extraction
followed by liquid chromatography tandem mass spec-
trometry (LC-MS/MS) (Covance, Harrogate, UK). The
lower limit of quantification for GSK3008348 was 50 pg/
mL using a 50-μL aliquot of human plasma with an
upper limit of quantification of 50,000 pg/mL.
Statistical methods
A required sample size of five participants in the
GSK3008348 group was based on a within-subject stand-
ard deviation in uncorrected VT between two PET scans
of 0.15 and a minimum detectable reduction of 6.2%
[10]. The primary endpoint, change in uncorrected VT
at ~ 30min post-dose compared with pre-dose, was ana-
lysed using a Bayesian repeated measures model assum-
ing non-informative priors of the form N (mean = 0,
SD = 1000) for all model parameters and a Toeplitz co-
variance matrix. The analysis was based on the PET data
from the five participants who received GSK3008348.
Placebo participants were included primarily as a com-
parator for safety assessments. PET data from the pla-
cebo participants were included on plots for reference
but were not included in the analysis. The adjusted pos-
terior median value of VT ratio (PET 1/ Pre-dose PET)
was calculated together with corresponding standard de-
viation and 95% highest posterior density (HPD) credible
interval (CrI). The posterior probability that the true ra-
tio PET1/Pre-dose is less than 1 (= true % reduction in
VT at ~ 30 min compared to Pre-dose > 0%) was
calculated and the pre-defined study success criterion
was defined as a posterior probability ≥80%. The same
Bayesian model was used for the analysis of all other
PET derived endpoints.
Safety data were summarised descriptively. GSK3008348
plasma concentration-time data were analysed using stand-
ard non-compartmental analysis (WinNonlin Version 7.0).
Key parameters derived were: area under the concentration-
time curve from time zero to t, where t is the time of the last
quantifiable concentration (AUC0-t), maximum plasma con-
centration (Cmax) and time to Cmax (Tmax).
Results
Participant characteristics
A total of eight participants were randomised, five to
GSK3008348 and three to placebo; seven completed the
study with a PET scan at ~ 30min post dose (PET 1).
Four participants (3 active, 1 placebo) underwent the ~
24 h post dose scan (PET 2). One participant in the pla-
cebo group was withdrawn due to PET equipment fail-
ures as the post dose PET scans could not be
rescheduled within the limits of the protocol. The ma-
jority of participants were male (7 of 8) with a mean age
of 70 and 74 years in the placebo and GSK3008348
groups, respectively (Table 1). Median (range) percent
predicted FVC was relatively well preserved in both
groups (Placebo: 93% (78–94%); GSK300348: 91% (79–
113%)) whilst median (range) DLCO was reduced (Pla-
cebo: 43% (43–50%); GSK300348: 48% (42–54%)).
PET imaging results
After single nebulised dosing with GSK3008348, adjusted
median uncorrected VT at ~ 30min post-dose decreased
from 1.50mL/cm3 to 1.20mL/cm3 and a reduction in un-
corrected VT was observed in all participants in the
GSK3008348 group (Fig. 2; Additional File 1, Table S1).
The adjusted posterior median reduction was 20% (95%
HPD CrI: − 9 to 42%) and the posterior probability that
the true % reduction at ~ 30min post-dose compared with
pre-dose > 0%, was 93%, meeting the pre-defined study
success criterion (Table 2). The estimated standard devi-
ation of log (PET1/Pre-dose) was 0.16 (Table 2). Three of
the five participants receiving GSK3008348 had a PET
scan at the ~ 24 h timepoint (PET 2) and for all three, un-
corrected VT increased from the ~ 30min post-dose levels
(Fig. 2) with a median adjusted VT of 1.72mL/cm
3 at this
time point (Additional File 1, Table S1). The estimated ad-
justed posterior median ratio of PET2/pre-dose was 1.154
(95% HPD CrI: 0.791, 1.647) and the posterior probability
that the true % reduction at ~ 24 h post-dose compared
with pre-dose > 0%, was 18% (Table 2).
Data for air-corrected VT showed a similar pattern to
uncorrected VT with a decrease in signal between PET1
and pre-dose (Additional File 2, Figure S1). However,
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the results for SUV (air-corrected and uncorrected)
showed a different pattern to the VT and did not show a
decrease in signal between PET 1 and pre-dose (Add-
itional File 3, Figure S2a and Figure S2b).
Safety results
Six AEs were reported across four participants, three
in the GSK3008348 group and one in the placebo
group (Table 3). All AEs were mild in intensity and
none were considered treatment related. There were
no SAEs reported and no participant withdrawals
from the study as a result of safety findings. Further-
more, no clinically significant abnormalities that were
attributable to study treatment were reported for clin-
ical laboratory evaluations, ECGs, vital signs or lung
function assessments.





Age (years), mean (SD) 70.3 (3.1) 73.6 (2.3)
Males, n (%) 3 (100) 4 (80)
BMI (kg/m2), mean (SD) 31.4 (1.1) 27.9 (1.9)
Race, n (%)
White/Caucasian/European heritage 3 (100) 5 (100)
Lung function
FVC percent predicted (%), median (range)
FEV1 percent predicted (%), median (range)







BMI body mass index
Fig. 2 Summary of adjusted medians of uncorrected VT, (mL/cm3) of [18F]FBA20FMDV2 and individual patient profiles. PET1: PET scan on day 1
at ~30 min post-dose; PET2: PET scan on day 2 at ~24 h post-dose. The adjusted medians (with 95% Cr I) were calculated from a Bayesian
repeated measures model using data from participants on the GSK3008348 1000 mcg arm only and is indicated by a thicker line and filled
triangles. Data for individual participants dosed with GSK300834 are shown with dotted lines linking the data. Individual subject data is shown for
participants on GSK3008348 1000 mcg (red symbols) and placebo (green symbols). The PET data from the placebo participants are included on
plots for reference, but were not included in the analysis.
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Pharmacokinetic results
The plasma concentration-time profiles indicated rapid
absorption of GSK3008348 (median Tmax of 0.5 h)
followed by a rapid decline in plasma concentrations up
to 4 h post-dose and a slower decline thereafter (Fig. 3,
Table 4). Plasma concentrations were measurable up to
24 h post-dose in period 1 and 30 h post-dose in period
2 with the exception of two participants whose last sam-
pling time was 22 h. Systemic exposure to GSK3008348,
as measured by geometric mean AUC0-t and Cmax did
not appear markedly different between Dosing periods 1
and 2. Between subject variability (%CVb) in total sys-
temic exposure (AUC0-t and Cmax) to GSK3008348 was
moderate (range 31 to 58%).
Discussion
This was the first study to evaluate the effects of the in-
haled αvβ6 integrin inhibitor, GSK3008348, in an IPF
population not currently treated with pirfenidone or nin-
tedanib. The participants in this study were typical of an
IPF population, 80% male and with a mean age > 70
years. The majority of participants had preserved FVC
(median % predicted > 90%) but significantly impaired
DLCO (median % predicted of 43.3% in the placebo
group and 48% in the active treatment group) demon-
strating the impact of fibrosis on gas transfer. A single
nebulised 1000 mcg dose of GSK3008348 inhibited the
uptake of the specific PET ligand [18F]FB-A20FMDV2 in
the lung at ~ 30 min post-dose, providing evidence of
target engagement with the αvβ6 integrin receptor, but
not at ~ 24 h, indicating that the duration of target
engagement was less than 24 h, consistent with a priori
PK/PD modelling. Single doses of 1000 mcg of
GSK3008348 were well tolerated, and PK was generally
consistent with that observed for healthy volunteers [8].
All participants dosed with GSK3008348 showed a re-
duction in uncorrected VT, the primary endpoint, thus
supporting the robustness of this finding. It is recognised
that the treatment response differed between partici-
pants. It is difficult to explain the reasons for this in such
a small study, but possible explanations include differ-
ences in drug exposure in the lungs and disease severity
or activity. The variability (SD) of the data in the active
group was 0.16, comparing favourably with the value of
0.15 assumed in the sample size calculations during study
design, which were based on the test-retest variability
measured in a previous enabling study, where PET scans
were repeated ~ 12 days apart in patients with IPF [10].
The rationale for selecting uncorrected VT as the pri-
mary endpoint was well considered when designing this
study. IPF is characterized by interstitial pneumonia to-
gether with fibrosis and the distribution of air, fibrosis
and blood in the lung varies according to the stage of fi-
brosis, all important factors to consider when interpret-
ing lung [18F]FB-A20FMDV2 uptake [14]. VT was
chosen as the appropriate measure to assess the uptake
of the αvβ6 PET ligand as, unlike SUV, it accounts for
any distributional changes in the ligand that may be
caused by a therapeutic αvβ6 inhibitor. This selection
was corroborated as SUV indeed showed a different pat-
tern to the VT and did not decrease between PET 1 and
pre-dose, strongly suggesting that distributional changes
were relevant as expected.
The decision to use uncorrected rather than air-
corrected VT as the primary endpoint was based on the
assumption that the fraction of air in the lung would be
unchanged for an individual participant in this short-
duration study. The relative changes in the post-dose
air-corrected VT were similar to those for uncorrected
VT, justifying this assumption. As the reduction from
pre-dose to ~ 30-min post-dose air-corrected VT also
met the pre-defined success criterion, this further sup-
ported the primary endpoint results.
The data presented here are insufficient alone to allow
interpretation of how the 20% reduction in uncorrected
VT relates to the level of target engagement. However,
putting these results into context, it is comparable to the
17% difference seen between IPF and healthy participants
Table 2 Adjusted posterior median ratios of uncorrected VT (mL/cm
3)
Parameter Adjusted Median of Ratio 95% HPD CrI of Ratio SD Logs of Ratio Probability (True Ratio < 1.0)
PET1/Pre-dose 0.797 (0.578, 1.087) 0.1576 0.934
PET2/Pre-dose 1.154 (0.791, 1.647) 0.1779 0.175
PET2/PET1 1.446 (0.984, 2.083) 0.1868 0.030
HPD Crl Highest posterior density credible interval; PET positron emission tomography; PET1 PET scan on day 1 at ~ 30 min post-dose (n = 5); PET2 PET scan on day
2 at ~ 24 h post-dose (n = 3)
PET data from the placebo participants were included on plots for reference but were not included in the analysis






Number of participants with any AE, n (%) 1 (33) 3 (60)
Diarrhoea 1 (33) 0
Urinary tract infection 0 1 (20)
Headache 0 1 (20)
Contact dermatitis 0 1 (20)
Tooth extraction 0 1 (20)
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in air-corrected VT [10], suggesting that it is a meaningful
change. In making this comparison it is important to con-
sider that some of the difference in PET signal between
IPF and healthy participants will be due to reduced air
fraction in IPF lungs, hence the difference in air-corrected
VT (which is smaller than the difference in uncorrected
VT) is the appropriate comparator. In any case, the
consistency in the relative change of uncorrected and air-
corrected VT values in the current study add further cre-
dence to the robustness of the result.
Data on uncorrected VT at ~ 24 h post-dose, available for
three out of five participants receiving GSK3008348,
returned to approximate baseline levels - in line with a priori
modelling that indicated the duration of action would be
less than 24 h and hence not supporting a once daily dosing
regimen for this drug. However, further study would be re-
quired to characterise the drug’s duration of action fully.
In this preliminary study in IPF patients, inhaled
GSK3008348 was well tolerated with no AEs or clinically
relevant findings attributable to treatment. The PK profile
following single inhaled dosing demonstrated rapid
absorption and multi-phasic elimination of GSK3008348.
Furthermore, there was significant overlap in systemic ex-
posure (Cmax and AUC) to GSK3008348 in IPF patients
compared with healthy participants following a 1000 mcg
single dose [8].
Conclusion
This first-time in patient IPF study successfully dem-
onstrated that a nebulised 1000 mcg dose of
GSK3008348 inhibited the uptake in the lung of a
target-specific PET ligand for the αvβ6 integrin at ~
30 min but not at ~ 24 h post-dose, providing evi-
dence of target engagement and indicating a duration
of target engagement of less than 24 h. Further study
would be required to confirm the level of target en-
gagement and to assess its impact on downstream
pharmacology. GSK3008348 was well tolerated and
PK was consistent with the PK profile shown in
healthy subjects. To the best of our knowledge, this is
the first time that a target-specific radioligand has
been used to assess target engagement of a putative
Fig. 3 Median plasma GSK3008348 concentration-time plot
Table 4 Summary of Derived Plasma GSK3008348 Pharmacokinetic Parameters
PK Parameter (units) N Period Geometric Mean 95% CI %CVb
AUC(0-t)
(h*pg/mL)
5 Period 1 64,638 (33,065, 126,362) 58
5 Period 2 66,123 (39,036, 112,005) 44
Cmax
(pg/mL)
5 Period 1 14,050 (8876, 22,243) 38




5 Period 1 0.50 (0.4–0.5)
5 Period 2 0.47 (0.4–0.5)
AUC0–t area under the concentration-time curve from time zero to time of last quantifiable concentration; Cmax maximum plasma concentration; Tmax time to
maximum plasma concentration
1Tmax expressed as median (range)
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therapeutic compound in the lung, demonstrating
proof of principle that PET imaging can enhance the
understanding of pharmacology in early pulmonary
drug development.
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